Layal Bou Harfouch
Drug Policy Analyst, Reason Foundation
Layal Bou Harfouch is a drug policy analyst at Reason Foundation.
Her work for Reason focuses on harm reduction. Bou Harfouch’s experience spans multiple facets of addiction treatment and drug policy, informed by her extensive background in translational health research and clinical coordination.
Bou Harfouch previously coordinated multisite clinical trials in addiction at Johns Hopkins University School of Medicine, Division of Addiction Medicine, where she served as a senior clinical research coordinator testing a monthly injectable formulation of buprenorphine. She most recently held a position as a research coordinator at the Adolescent Addiction Recovery Center at Detroit Medical Center, where she analyzed clinic outcomes and success rates.
Bou Harfouch holds an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Kinesiology with a minor in Substance Use Disorder Prevention, Intervention, and Treatment from Central Michigan University.
Outside of her professional life, Bou Harfouch is dedicated to self-care and wellness practices, including yoga, and she cherishes spending quality time with her family. These pursuits provide her with balance and fulfillment, supporting her in both her personal and professional endeavors.
-
How bad housing policy fuels homelessness, and how to fix it
Integrating harm reduction strategies with housing first models may create a sustainable path forward that is both compassionate and effective.
-
Will Martin Makary’s FDA listen to the evidence on e-cigarettes?
Instead of demonizing e-cigarettes, Trump's FDA should recognize them as a resource for public health.
-
Medicaid is failing people leaving prison, and we’re all paying the price
Addressing Medicaid’s shortcomings isn’t just about fiscally responsible solutions; it’s about empowering individuals to jumpstart their reentry to society.
-
RFK Jr.’s opioid crisis plan
While Kennedy's opioid recovery journey may have worked for him, his proposal overlooks other evidence-based approaches.
-
Nonconsensual drug testing raises serious ethical concerns
When hospitals take on roles similar to law enforcement, they betray their core mission: delivering compassionate, patient-centered care.
-
Harm reduction recommendations for the Trump administration
It's time for a comprehensive drug policy that makes meaningful strides toward reducing overdose deaths, supporting recovery, and fostering healthier, more resilient communities.
-
Unreliable drug tests shouldn’t be used to separate mothers from their newborns
Informed consent and confirmatory testing should be standards for any drug testing that could affect a mother’s parental rights.
-
Why smoking cessation programs should embrace vaping
Contrary to widespread belief, there is substantial proof that e-cigarettes are a viable and successful cessation tool.
